# C_2009201EN.01001201.xml

| 26.8.2009 | EN | Official Journal of the European Union | C 201/12 |
| --- | --- | --- | --- |

26.8.2009

EN

Official Journal of the European Union

C 201/12

---

Prior notification of a concentration

(Case COMP/M.5555 — Novartis/Ebewe Spezial-Pharma Holding)

(Text with EEA relevance)

2009/C 201/10

| 1. | On 18 August 2009, the Commission received a notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1) by which the Novartis Group, Switzerland, acquires within the meaning of Article 3(1)(b) of the Council Regulation control of the whole of the Ebewe SP Group, Austria by way of purchase of shares. |
| --- | --- |

1.

On 18 August 2009, the Commission received a notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1) by which the Novartis Group, Switzerland, acquires within the meaning of Article 3(1)(b) of the Council Regulation control of the whole of the Ebewe SP Group, Austria by way of purchase of shares.

1

| 2. | The business activities of the undertakings concerned are:






  — | for Novartis Group: active in the development, production and distribution of medical products, including prescription drugs, over-the-counter (‘OTC’) drugs, human vaccines and animal health products, |
| --- | --- | --- |

2.

The business activities of the undertakings concerned are:

—

for Novartis Group: active in the development, production and distribution of medical products, including prescription drugs, over-the-counter (‘OTC’) drugs, human vaccines and animal health products,

| — | for Ebewe SP Group: active in the manufacture and distribution of specialty generic pharmaceutical products as well as in contract manufacturing of finished dose pharmaceuticals for other pharmaceutical companies. |
| --- | --- |

—

for Ebewe SP Group: active in the manufacture and distribution of specialty generic pharmaceutical products as well as in contract manufacturing of finished dose pharmaceuticals for other pharmaceutical companies.

| 3. | On preliminary examination, the Commission finds that the notified transaction could fall within the scope of Regulation (EC) No 139/2004. However, the final decision on this point is reserved. |
| --- | --- |

3.

On preliminary examination, the Commission finds that the notified transaction could fall within the scope of Regulation (EC) No 139/2004. However, the final decision on this point is reserved.

| 4. | The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.
  Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent to the Commission by fax (+32 22964301 or 22967244) or by post, under reference number COMP/M.5555 — Novartis/Ebewe Spezial-Pharma Holding, to the following address:





  European Commission |
| --- | --- |
| Directorate-General for Competition |
| Merger Registry |
| 1049 Bruxelles/Brussel |
| BELGIQUE/BELGIË |

4.

The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.

Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent to the Commission by fax (+32 22964301 or 22967244) or by post, under reference number COMP/M.5555 — Novartis/Ebewe Spezial-Pharma Holding, to the following address:

European Commission

Directorate-General for Competition

Merger Registry

1049 Bruxelles/Brussel

BELGIQUE/BELGIË

---

(1)  OJ L 24, 29.1.2004, p. 1.

1

---